An early-stage venture capital firm founded in 2008 and based in San Francisco, CA has recently closed a $125M fund, and will invest in series A rounds with initial investments in the range of $2M-$5M, with access to additional capital for follow-on investments if needed. The firm prefers priced equity rounds, and acts nearly exclusively as a lead investor.
The firm is traditionally a tech-oriented VC, however the firm is open to evaluating companies in the health IT space, whether they are developing consumer facing products or enterprise solutions for health systems with the caveat being that the core business can scale with capital efficiency. The firm is looking for capital efficient technology solutions, with the number one disqualifier of potential portfolio companies being capital intensity.
The firm is most interested in U.S. companies, and will consider companies located globally only if they are based near a trusted colleague/investor that can interact with the company. While the firm values experienced entrepreneurs with an exit on their résumé, the firm is open to working with entrepreneurs of all experience levels.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment